My Bibliography

select

Iwamoto T, You M, Li E, Spangler J, Tomich JM, Hristova K. Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications. Biochim Biophys Acta. 2005 Mar 1;1668(2):240-7. doi: 10.1016/j.bbamem.2004.12.012. Epub 2005 Jan 28. PubMed PMID: 15737335.

select

You M, Spangler J, Li E, Han X, Ghosh P, Hristova K. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers. Biochemistry. 2007 Oct 2;46(39):11039-46. doi: 10.1021/bi700986n. Epub 2007 Sep 11. PubMed PMID: 17845056.

select

Engineered proteins including mutant fibronectin domains. USA patent application PCT/US10/45490. 2010.

select

Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13252-7. doi: 10.1073/pnas.0913476107. Epub 2010 Jul 7. PubMed PMID: 20616078; PubMed Central PMCID: PMC2922117.

select

Bispecific antibodies directed against tyrosine kinase receptors. USA patent application PCT/US2011/048529. 2011.

select

Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol. 2012 Sep 28;422(4):532-44. doi: 10.1016/j.jmb.2012.06.014. Epub 2012 Jun 15. PubMed PMID: 22706026; PubMed Central PMCID: PMC4041985.

select

Spangler JB, Feltus FA. Conserved Non-Coding Sequences are Associated with Rates of mRNA Decay in Arabidopsis. Front Plant Sci. 2013;4:129. doi: 10.3389/fpls.2013.00129. eCollection 2013. PubMed PMID: 23675377; PubMed Central PMCID: PMC3650315.

select

Moraga I, Spangler J, Mendoza JL, Garcia KC. Multifarious determinants of cytokine receptor signaling specificity. Adv Immunol. 2014;121:1-39. doi: 10.1016/B978-0-12-800100-4.00001-5. Review. PubMed PMID: 24388212; PubMed Central PMCID: PMC4449261.

select

Spangler JB, Moraga I, Mendoza JL, Garcia KC. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139-67. doi: 10.1146/annurev-immunol-032713-120211. Epub 2014 Dec 10. Review. PubMed PMID: 25493332; PubMed Central PMCID: PMC4445396.

select

Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, Votavova P, Pepper M, Kovar M, Garcia KC. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity. 2015 May 19;42(5):815-25. doi: 10.1016/j.immuni.2015.04.015. PubMed PMID: 25992858; PubMed Central PMCID: PMC4439582.

select

Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 2015 May 19;42(5):826-38. doi: 10.1016/j.immuni.2015.04.018. PubMed PMID: 25992859; PubMed Central PMCID: PMC4560365.

select

Moraga I, Spangler JB, Mendoza JL, Gakovic M, Wehrman TS, Krutzik P, Garcia KC. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. Elife. 2017 May 12;6. doi: 10.7554/eLife.22882. PubMed PMID: 28498099; PubMed Central PMCID: PMC5429090.

select

Kureshi R, Bahri M, Spangler JB. Reprogramming immune proteins as therapeutics using molecular engineering. Current opinion in chemical engineering. 2018 March; 19:27-34.

select

Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. J Immunol. 2018 Oct 1;201(7):2094-2106. doi: 10.4049/jimmunol.1800578. Epub 2018 Aug 13. PubMed PMID: 30104245; PubMed Central PMCID: PMC6173196.

select

Yang H, Kureshi R, Spangler JB. Structural Basis for Signaling Through Shared Common γ Chain Cytokines. Adv Exp Med Biol. 2019;1172:1-19. doi: 10.1007/978-981-13-9367-9_1. Review. PubMed PMID: 31628649.

select

Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJL, Dougan M, Garcia KC, Baker D. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019 Jan;565(7738):186-191. doi: 10.1038/s41586-018-0830-7. Epub 2019 Jan 9. PubMed PMID: 30626941; PubMed Central PMCID: PMC6521699.

select

Leonard EK, Leff MI, Spangler JB. Weaponizing T-cell receptors through molecular engineering. J Biol Chem. 2019 Apr 12;294(15):5805-5806. doi: 10.1074/jbc.H119.008479. PubMed PMID: 30979848; PubMed Central PMCID: PMC6463730.

select

Spangler JB, Moraga I, Jude KM, Savvides CS, Garcia KC. A strategy for the selection of monovalent antibodies that span protein dimer interfaces. J Biol Chem. 2019 Sep 20;294(38):13876-13886. doi: 10.1074/jbc.RA119.009213. Epub 2019 Aug 6. PubMed PMID: 31387945; PubMed Central PMCID: PMC6755802.

select

Krohl PJ, Ludwig SD, Spangler JB. Emerging technologies in protein interface engineering for biomedical applications. Curr Opin Biotechnol. 2019 Dec;60:82-88. doi: 10.1016/j.copbio.2019.01.017. Epub 2019 Feb 23. Review. PubMed PMID: 30802788.

select

Krohl P, Kim K, Lew L, VanDyke D, Ludwig S, Spangler J. A suspension cell-based interaction platform for interrogation of membrane proteins. AIChE journal. American Institute of Chemical Engineers. 2020; 66(12):e16995.

select

Tomala J, Spangler JB. Characterization of Immune Cell Subset Expansion in Response to Therapeutic Treatment in Mice. Methods Mol Biol. 2020;2111:101-114. doi: 10.1007/978-1-0716-0266-9_9. PubMed PMID: 31933202.

select

Kureshi R, Zhu A, Shen J, Tzeng SY, Astrab LR, Sargunas PR, Green JJ, Campochiaro PA, Spangler JB. Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases. Cell Mol Bioeng. 2020 Oct;13(5):405-418. doi: 10.1007/s12195-020-00641-0. eCollection 2020 Oct. PubMed PMID: 33184574; PubMed Central PMCID: PMC7596137.

select

VanDyke D, Wang W, Spangler J. Innovative synthetic signaling technologies for immunotherapy. Current opinion in biomedical engineering. 2020 December; 16:1-8.

select

Glassman CR, Mathiharan YK, Jude KM, Su L, Panova O, Lupardus PJ, Spangler JB, Ely LK, Thomas C, Skiniotis G, Garcia KC. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 2021 Feb 18;184(4):983-999.e24. doi: 10.1016/j.cell.2021.01.018. PubMed PMID: 33606986; PubMed Central PMCID: PMC7899134.

select

Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, Sen R, Doucet M, De Silva RA, Mease RC, Forde PM, Jaffee EM, Desai P, Ganguly S, Gabrielson E, Vaidya D, Spangler JB, Nimmagadda S. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37). doi: 10.1073/pnas.2107982118. PubMed PMID: 34508005; PubMed Central PMCID: PMC8449349.

select

Bernstein ZJ, Spangler JB. Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies. J Clin Invest. 2021 Oct 1;131(19). doi: 10.1172/JCI152857. PubMed PMID: 34596048; PubMed Central PMCID: PMC8483744.

select

Sargunas PR, Spangler JB. Full speed AHEAD in antibody discovery. Nat Chem Biol. 2021 Oct;17(10):1011-1012. doi: 10.1038/s41589-021-00838-y. PubMed PMID: 34211163.

select

Silver AB, Leonard EK, Gould JR, Spangler JB. Engineered antibody fusion proteins for targeted disease therapy. Trends Pharmacol Sci. 2021 Dec;42(12):1064-1081. doi: 10.1016/j.tips.2021.09.009. Epub 2021 Oct 25. Review. PubMed PMID: 34706833; PubMed Central PMCID: PMC8922469.

select

Ludwig SD, Bernstein ZJ, Agatemor C, Dammen-Brower K, Ruffolo J, Rosas JM, Post JD, Cole RN, Yarema KJ, Spangler JB. A versatile design platform for glycoengineering therapeutic antibodies. MAbs. 2022 Jan-Dec;14(1):2095704. doi: 10.1080/19420862.2022.2095704. PubMed PMID: 35815437; PubMed Central PMCID: PMC9272841.

select

Krohl PJ, Spangler JB. A Hybrid Adherent/Suspension Cell-Based Selection Strategy for Discovery of Antibodies Targeting Membrane Proteins. Methods Mol Biol. 2022;2491:195-216. doi: 10.1007/978-1-0716-2285-8_11. PubMed PMID: 35482192; PubMed Central PMCID: PMC9667817.

select

Dammen-Brower K, Epler P, Zhu S, Bernstein ZJ, Stabach PR, Braddock DT, Spangler JB, Yarema KJ. Strategies for Glycoengineering Therapeutic Proteins. Front Chem. 2022;10:863118. doi: 10.3389/fchem.2022.863118. eCollection 2022. Review. PubMed PMID: 35494652; PubMed Central PMCID: PMC9043614.

select

Casciola-Rosen L, Thiemann DR, Andrade F, Trejo-Zambrano MI, Leonard EK, Spangler JB, Skinner NE, Bailey J, Yegnasubramanian S, Wang R, Vaghasia AM, Gupta A, Cox AL, Ray SC, Linville RM, Guo Z, Searson PC, Machamer CE, Desiderio S, Sauer LM, Laeyendecker O, Garibaldi BT, Gao L, Damarla M, Hassoun PM, Hooper JE, Mecoli CA, Christopher-Stine L, Gutierrez-Alamillo L, Yang Q, Hines D, Clarke WA, Rothman RE, Pekosz A, Fenstermacher KZ, Wang Z, Zeger SL, Rosen A. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022 May 9;7(9). doi: 10.1172/jci.insight.158362. PubMed PMID: 35349483; PubMed Central PMCID: PMC9090251.

select

de Rutte J, Dimatteo R, Archang MM, van Zee M, Koo D, Lee S, Sharrow AC, Krohl PJ, Mellody M, Zhu S, Eichenbaum JV, Kizerwetter M, Udani S, Ha K, Willson RC, Bertozzi AL, Spangler JB, Damoiseaux R, Di Carlo D. Suspendable Hydrogel Nanovials for Massively Parallel Single-Cell Functional Analysis and Sorting. ACS Nano. 2022 May 24;16(5):7242-7257. doi: 10.1021/acsnano.1c11420. Epub 2022 Mar 24. PubMed PMID: 35324146; PubMed Central PMCID: PMC9869715.

select

Leonard EK, Aller Pellitero M, Juelg B, Spangler JB, Arroyo-Currás N. Antibody-Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers. J Am Chem Soc. 2022 Jun 29;144(25):11226-11237. doi: 10.1021/jacs.2c02537. Epub 2022 Jun 8. PubMed PMID: 35675509; PubMed Central PMCID: PMC9199438.

select

Sargunas PR, Spangler JB. Joined at the hip: The role of light chain complementarity determining region 2 in antibody self-association. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2208330119. doi: 10.1073/pnas.2208330119. Epub 2022 Jul 1. PubMed PMID: 35776537; PubMed Central PMCID: PMC9282379.

select

Luly KM, Yang H, Lee SJ, Wang W, Ludwig SD, Tarbox HE, Wilson DR, Green JJ, Spangler JB. Poly(Beta-Amino Ester)s as High-Yield Transfection Reagents for Recombinant Protein Production. Int J Nanomedicine. 2022;17:4469-4479. doi: 10.2147/IJN.S377371. eCollection 2022. PubMed PMID: 36176585; PubMed Central PMCID: PMC9514136.

select

Isser A, Silver AB, Pruitt HC, Mass M, Elias EH, Aihara G, Kang SS, Bachmann N, Chen YY, Leonard EK, Bieler JG, Chaisawangwong W, Choy J, Shannon SR, Gerecht S, Weber JS, Spangler JB, Schneck JP. Nanoparticle-based modulation of CD4(+) T cell effector and helper functions enhances adoptive immunotherapy. Nat Commun. 2022 Oct 14;13(1):6086. doi: 10.1038/s41467-022-33597-y. PubMed PMID: 36241639; PubMed Central PMCID: PMC9568616.

select

VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry JA, Gebara E, Cross AR, Cheung LS, Dykema AG, Orcutt-Jahns BT, Henclová T, Golias J, Balolong J, Tomasovic LM, Funda D, Meyer AS, Pardoll DM, Hester J, Issa F, Hunter CA, Anderson MS, Bluestone JA, Raimondi G, Spangler JB. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 2022 Oct 18;41(3):111478. doi: 10.1016/j.celrep.2022.111478. PubMed PMID: 36261022; PubMed Central PMCID: PMC9631798.

select

Bokhari RS, Beheshti A, Blutt SE, Bowles DE, Brenner D, Britton R, Bronk L, Cao X, Chatterjee A, Clay DE, Courtney C, Fox DT, Gaber MW, Gerecht S, Grabham P, Grosshans D, Guan F, Jezuit EA, Kirsch DG, Liu Z, Maletic-Savatic M, Miller KM, Montague RA, Nagpal P, Osenberg S, Parkitny L, Pierce NA, Porada C, Rosenberg SM, Sargunas P, Sharma S, Spangler J, Tavakol DN, Thomas D, Vunjak-Novakovic G, Wang C, Whitcomb L, Young DW, Donoviel D. Looking on the horizon; potential and unique approaches to developing radiation countermeasures for deep space travel. Life Sci Space Res (Amst). 2022 Nov;35:105-112. doi: 10.1016/j.lssr.2022.08.003. Epub 2022 Aug 7. PubMed PMID: 36336356.

select

Yang H, Karl MN, Wang W, Starich B, Tan H, Kiemen A, Pucsek AB, Kuo YH, Russo GC, Pan T, Jaffee EM, Fertig EJ, Wirtz D, Spangler JB. Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. Mol Ther. 2022 Nov 2;30(11):3430-3449. doi: 10.1016/j.ymthe.2022.07.008. Epub 2022 Jul 16. PubMed PMID: 35841152; PubMed Central PMCID: PMC9637575.

select

VanDyke D, Taylor JD, Kaeo KJ, Hunt J, Spangler JB. Biologics-based degraders - an expanding toolkit for targeted-protein degradation. Curr Opin Biotechnol. 2022 Dec;78:102807. doi: 10.1016/j.copbio.2022.102807. Epub 2022 Sep 27. Review. PubMed PMID: 36179405; PubMed Central PMCID: PMC9742328.

select

Anderson CF, Wang Q, Stern D, Leonard EK, Sun B, Fergie KJ, Choi CY, Spangler JB, Villano J, Pekosz A, Brayton CF, Jia H, Cui H. Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. Matter. 2023 Feb 1;6(2):583-604. doi: 10.1016/j.matt.2022.11.027. Epub 2022 Dec 12. PubMed PMID: 36531610; PubMed Central PMCID: PMC9743467.

select

Deckers J, Anbergen T, Hokke AM, de Dreu A, Schrijver DP, de Bruin K, Toner YC, Beldman TJ, Spangler JB, de Greef TFA, Grisoni F, van der Meel R, Joosten LAB, Merkx M, Netea MG, Mulder WJM. Engineering cytokine therapeutics. Nat Rev Bioeng. 2023;1(4):286-303. doi: 10.1038/s44222-023-00030-y. Epub 2023 Feb 16. Review. PubMed PMID: 37064653; PubMed Central PMCID: PMC9933837.

select

Krohl PJ, Fine J, Yang H, VanDyke D, Ang Z, Kim KB, Thomas-Tikhonenko A, Spangler JB. Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach. Cell Rep Methods. 2023 Mar 27;3(3):100429. doi: 10.1016/j.crmeth.2023.100429. eCollection 2023 Mar 27. PubMed PMID: 37056366; PubMed Central PMCID: PMC10088246.

select

Silver AB, Wang J, Spangler JB. Masking T cell engagers mitigates on-target off-tumor activity. Nat Cancer. 2023 Apr;4(4):439-441. doi: 10.1038/s43018-023-00529-8. PubMed PMID: 36997746.

select

Quijano-Rubio A, Bhuiyan AM, Yang H, Leung I, Bello E, Ali LR, Zhangxu K, Perkins J, Chun JH, Wang W, Lajoie MJ, Ravichandran R, Kuo YH, Dougan SK, Riddell SR, Spangler JB, Dougan M, Silva DA, Baker D. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nat Biotechnol. 2023 Apr;41(4):532-540. doi: 10.1038/s41587-022-01510-z. Epub 2022 Oct 31. PubMed PMID: 36316485; PubMed Central PMCID: PMC10110466.

select

Leonard EK, Tomala J, Gould JR, Leff MI, Lin JX, Li P, Porter MJ, Johansen ER, Thompson L, Cao SD, Henclova T, Huliciak M, Vaněk O, Kovar M, Leonard WJ, Spangler JB. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity. bioRxiv. 2023 May 4;. doi: 10.1101/2023.05.03.539272. PubMed PMID: 37205604; PubMed Central PMCID: PMC10187205.

select

Rhodes KR, Tzeng SY, Iglesias M, Lee D, Storm K, Neshat SY, VanDyke D, Lowmaster SM, Spangler JB, Raimondi G, Green JJ. Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis. Sci Adv. 2023 Jun 2;9(22):eadd8693. doi: 10.1126/sciadv.add8693. Epub 2023 Jun 2. PubMed PMID: 37267370; PubMed Central PMCID: PMC10413683.

select

Yang H, Ulge UY, Quijano-Rubio A, Bernstein ZJ, Maestas DR, Chun JH, Wang W, Lin JX, Jude KM, Singh S, Orcutt-Jahns BT, Li P, Mou J, Chung L, Kuo YH, Ali YH, Meyer AS, Grayson WL, Heller NM, Garcia KC, Leonard WJ, Silva DA, Elisseeff JH, Baker D, Spangler JB. Design of cell-type-specific hyperstable IL-4 mimetics via modular de novo scaffolds. Nat Chem Biol. 2023 Sep;19(9):1127-1137. doi: 10.1038/s41589-023-01313-6. Epub 2023 Apr 6. PubMed PMID: 37024727; PubMed Central PMCID: PMC10697138.

select

Dykema AG, Zhang J, Cheung LS, Connor S, Zhang B, Zeng Z, Cherry CM, Li T, Caushi JX, Nishimoto M, Munoz AJ, Ji Z, Hou W, Zhan W, Singh D, Zhang T, Rashid R, Mitchell-Flack M, Bom S, Tam A, Ionta N, Aye THK, Wang Y, Sawosik CA, Tirado LE, Tomasovic LM, VanDyke D, Spangler JB, Anagnostou V, Yang S, Spicer J, Rayes R, Taube J, Brahmer JR, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN. Lung tumor-infiltrating T(reg) have divergent transcriptional profiles and function linked to checkpoint blockade response. Sci Immunol. 2023 Sep 15;8(87):eadg1487. doi: 10.1126/sciimmunol.adg1487. Epub 2023 Sep 15. PubMed PMID: 37713507; PubMed Central PMCID: PMC10629528.